Since its introduction in the early 1970s, bone marrow for chronic myeloid leukemia. A retrospective analysis transplantation (BMT) for hematological malignancies has was carried out of the outcome of 373 consecutive transgained wide acceptance. It is generally considered as the plants performed at 38 European institutions between only form of therapy with the capacity to cure chronic mye-1980 and 1988 and reported to the registry of the Eurologenous leukemia (CML). During the last decade new pean Group for Blood and Marrow Transplantation. All approaches such as the combined use of cyclosporin A transplants were carried out for first chronic phase of (CsA) and methotrexate (MTX) for graft-versus-host dischronic myelogenous leukemia using unmanipulated ease (GVHD) prophylaxis have reduced treatment-related marow cells from HLA-identical sibling donors. The mortality (TRM) and improved outcome. 1,2 Other developprobability of survival and leukemia-free survival at 8 ments such as T cell depletion have advanced our underyears were 54% (95% CI: 49-59) and 47% (95% CI:
of the EBMT in Leiden between 1980 and 1988. Data were disease recurrence; patients were censored at the time of relapse or at last follow-up. collected by questionnaire and included details of patient and donor age, sex and histocompatibility, WBC at diagnosis, duration of disease at the time of BMT, conditioning Molecular detection of BCR/ABL fusion gene regimen, GVHD prophylaxis and outcome. The follow-up was updated from October 1993.
RT/PCR for the BCR-ABL gene rearrangement was carried out on peripheral blood or bone marrow cells of 67 patients at eight institutions. All these centers used a sensitive twoPatients step PCR approach.
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The study population is a subset of a previous transplant cohort reported by EBMT in 1993. 8 This study focused on Statistical analyses the long-term outcome of a homogenous group of patients Outcome probabilities were calculated by the Kaplantransplanted for CML. The present study comprised a Meier method and comparisons were made using the log cohort of 373 patients transplanted in first chronic phase of rank test. 12 The primary outcome variables were analyzed CML from an HLA-identical sibling donor (male, n = 208; according to patient and donor sex, donor-recipient sex female, n = 165) using unmanipulated marrow cells. The combinations, method of GVHD prophylaxis (CsA/MTX conditioning regimen included in all cases cyclophosphavs CsA alone vs CsA/prednisolone), patient age (20 vs Ͼ20 mide and total body irradiation (TBI). Patients conditioned years), donor age (30 vs Ͼ30 years), (WBC at diagnosis with a non-TBI-conditioning regimen were excluded from (Ͻ30 × 10 9 /l vs Ͼ30 × 10 9 /l) and time interval from diagthe present analysis. GVHD prophylaxis consisted of CsA nosis to transplant (Ͻ12 months vs Ͼ12 months). Variables only (n = 211), CsA/prednisolone (n = 21) or CsA/MTX significant in univariate analyses at the P Ͻ 0.2 level were (n = 141). T cell-depleted transplants and patients receiving further examined using proportional hazards regression MTX only as GVHD prophylaxis were excluded from this analysis employing a backward stepping procedure to identanalysis. The median recipient age was 31.0 years (range ify the most statistically significant model. Interaction terms 2-50). Three hundred and nineteen patients were older than were added to the final model, but never reached statistical 20 years of age and 52 patients were younger. The median significance. In the analysis of early relapse, patients surdonor age was 30.5 years (range 1-62). The transplants viving more than 2 years were censored at 2 years. In the were carried out at 38 European institutions between 1980 analysis of late relapses, all patients surviving less than 2 and 1988. The time frame 1980 to 1988 was selected in years were excluded. Acute and chronic GVHD were order to allow for a median follow-up of 7 years. The parentered as time-dependent variables. All P values are twoticipating institutions and the number of patients transsided. 95% confidence intervals are quoted in parentheses. planted per center are listed in Appendix 1. Each team confirmed that all patients fulfilling the aforementioned criteria had indeed been reported to the EBMT. This study thereResults fore represents a consecutive series of patients with CML transplanted under similar and standard conditions. Patient
Overall results and donor characteristics are further detailed in Table 1 .
Of the 373 patients who received a transplant between 1980 and 1988, 203 patients are still alive and 170 have died.
Definition of endpoints
One hundred and seventy-eight patients are in continued complete remission. The overall actuarial probabilities of Primary outcome variables, ie survival, leukemia-free survival (LFS), transplant-related mortality (TRM), acute and survival and LFS at 8 years were 53.7% (CI: 49-59) and 46.7% (CI: 41-52) respectively ( Figure 1 and Table 1 ). The chronic GVHD and relapse, were all calculated from BMT. Leukemia-free survival was defined as survival without median LFS was 58 months. The median survival had not been attained at a median follow-up of 84 months (range: cytogenetic or hematologic evidence of leukemia. Acute and chronic GVHD were classified according to standard 35-154). The overall probability of TRM at 8 years was 40.6% (CI: 36-46) ( Table 1 and Figure 2 ). One hundred criteria as previously described. 9, 10 Patients were evaluable for acute and chronic GVHD if they had survived at least and fifty-five patients died a transplant-related death, while 15 died of relapse. The latest death occurred at 72 months 10 and 90 days respectively after marrow transplantation. Relapse was defined as the detection of Philadelphiapost-BMT. The main causes of death were GVHD and interstitial pneumonitis. These accounted for 54% of all positive metaphases in the marrow or abnormal blood/bone marrow counts or morphology consistent with CML. Disdeaths. Twenty-seven patients died more than 2 years after transplant. Leukemic relapse accounted for 41% of these ease recurrence within 2 years after BMT was classified as early relapse; late relapse was defined as recurrence of late deaths. The overall probabilities of developing acute GVHD (II-IV) at 100 days and chronic GVHD CML more than 2 years post-BMT. Transient relapse was diagnosed if there was recurrence of CML, as defined by (limited/extensive) at 4 years after transplant were 46.6% (CI. 41-52) and 52.1% (CI: 45-59) respectively (Table 2) . cytogenetic or morphological techniques, which resolved spontaneously without therapeutic intervention. Patients
Relapse of CML occurred in 40 patients. In a further seven cases a transient cytogenetic relapse was observed. Twentywith transient relapse were analyzed with the non-relapse group. TRM was defined as death due to causes other than four patients experienced relapse 2 years after BMT; 16 BMT for CML in first chronic phase.
Prognostic variables
Male recipients had significantly lower LFS compared to patients had relapse Ͼ2 years post-BMT. The latest documented relapse was at 6.5 years. The probabilities of females (40.7 vs 54.3%, P = 0.014). This could not be attributed to an increase in acute GVHD and both sexes had a relapse at 2 and 8 years were 10.0% (CI: 7-15) and 18.9% (CI: 14-25) respectively (Table 1 and Figure 2) . similar probability of developing acute GVHD (45.4 vs 48.1%, P = 0.42). The difference in LFS was explained by Recipient-donor sex combinations impacted significantly on transplant outcome after transplant. The LFS of female an increase in both TRM (45.7 vs 34.6%, P = 0.05) and relapse (23.1 vs 14.3%, P = 0.04) in males. Patient sex recipient-female donor pairs was 61.7% compared to only 37.9% for male-male pairs with an intermediate outcome remained a significant variable for both LFS and TRM in multivariate analysis (Table 3) .
for sex-mismatched combinations (Figure 3 ). Female- late relapse were transplanted from a male donor. The combined influence of these variables was that patients with no female pairs benefited from low TRM (30.0%) and relapse chronic GVHD and a male donor had an overall probability rate (9.1%). In contrast male-male pairs did not only have of relapse of 34.9% compared to only 5.1% for those with increased TRM (43.3%), but also experienced more leuany chronic GVHD and a female donor (P = 0.001) (Figure kemic relapses (31.3%) ( Table 1) . However, the probability 5). The duration of disease prior to transplant did not affect of leukemia relapse was not increased in male-female pairs.
relapse, even if the analysis was confined to patients with Patients transplanted within 12 months of diagnosis had no acute or chronic GVHD. The probabilities of 3-year sursignificantly better LFS (51.9 vs 44.2%, P = 0.03) which vival after early and late relapse had occurred were 38.0% was due to a decrease in TRM (34.3 vs 44.6%, P = 0.013).
(CI. 21-57) and 70% (CI: 44-88), respectively. There was a trend towards less acute GVHD if the transplant was carried out within 1 year of diagnosis (41.2 vs RT/PCR for BCR/ABL fusion gene 51.6%, P = 0.079). The combined impact of duration of disease and GVHD prophylaxis (CsA only vs CsA/MTX) Sixty-seven patients were studied by two-step RT/PCR for on LFS was also studied, but no significant differences BCR-ABL mRNA at a median of 114 months post-BMT were observed.
(range: 34-161). These patients were tested in eight differAcute GVHD grade II-IV affected LFS adversely in ent centers (Appendix 1). Sixty-one patients (91%) were multivariate analysis (RR = 0.36, P = 0.00001) which was PCR negative when last tested. Six patients were PCR posidue to a significant increase in TRM (II-IV vs 0-I, RR = tive at 39, 77, 84, 86, 126 and 138 months post-BMT. 4.0). Recipient age did not influence the probabilities of These patients remain in complete remission as defined in acute GVHD II-IV or chronic GVHD. There was a trend the Materials and methods section. towards improved survival if the transplant was carried out with immunosuppression consisting of CsA/MTX (60.9 vs 50.3%, P = 0.06). However, there was no significant difference in LFS (50.0 vs 44.7%, P = 0.18) between the CsA and CsA/MTX group. GVHD prophylaxis with CsA/MTX reduced both acute GVHD (49.8 vs 40.1%, P = 0.0002) and TRM (45.5 vs 32.9%, P = 0.04) in comparison to CsA only. In multivariate analysis the risk of developing acute GVHD II-IV remained reduced in the CsA/MTX group (CsA vs CsA/MTX; RR = 0.7, P = 0.028) and was also associated with less TRM (RR = 0.71, P = 0.53). However, the relapse rate in patients treated with CsA/MTX was significantly increased (25.6 vs 13.4%, P = 0.02) (Figure 4) . There was also a difference in chronic GVHD, but this was of borderline significance (P = 0.05).
Chronic GVHD and male donor sex were significant Male donor sex was a significant variable for late relapse
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Discussion
tance to prevent relapse of CML after marrow transplant. It seems reasonable to speculate that the low relapse rate The present study of a large, homogeneous cohort of in male-female pairs is due to recognition of the Y minor patients with CML in first chronic phase indicates that allohistocompatibility antigen on leukemia cells by lymphoid geneic marrow transplantation results in long-term diseasecells from the female donor. Surprisingly, a low relapse free survival in nearly half of the patients. This data is simirate was also observed in female-female pairs, which lar to the outcome reported in other large series.
13,14 The could be due to recognition of antigenic differences by median survival in this study had not yet been attained at female donor cells previously sensitized during preg-8 years. This compares favorably to median survivals rangnancy. However, it should be acknowledged that the regising from 66 to 72 months reported in recent large scale try did not contain details of the pregnancy record of the studies of patients treated conservatively with interferondonors which would have allowed for testing of this ␣.
15-17 Furthermore, over 90% of patients tested were negahypothesis. tive for the leukemia-specific BCR-ABL fusion message by
We observed that patients who were surviving more RT/PCR. This is in contrast to the findings during interthan 2 years post-BMT continued to relapse at a rate of feron-␣ therapy where molecular studies can detect perapproximately 1.5% per year until 6.5 years when the last sisting leukemia cells in virtually all patients. [18] [19] [20] The data relapse was observed. Late relapses after marrow transfrom this multicentre study support the notion that alloplant for CML may be more frequent than has been geneic marrow transplantation is the only therapy which can assumed hitherto. Enright et al 22 reported six relapses restore normal hematopoiesis to a substantial number of more than 5 years post-BMT in a cohort of 179 patients patients with CML.
transplanted from a sibling donor. These findings imply The present study reports parameters which influence that continued monitoring for late disease recurrence is LFS and which may assist in the timing of transplant and warranted. In our study residual leukemia cells were found donor selection. Recipient sex and acute GVHD proved to by RT/PCR for the BCR-ABL gene rearrangement in be significant determinants of LFS in multivariate analysis.
approximately 10% of disease-free survivors. Molecular Female recipients who did not develop acute GVHD (IIquantification of residual disease in two of these long-term IV) post marrow transplant achieved a leukemia-free sursurvivors confirmed that the leukemic clone persisted at vival of nearly 70%. Conversely, a LFS of only 38% was low levels more than 10 years after transplant. 23 However, observed in male recipients of male donor marrow which it is at present not certain if these patients indeed harbor was due to an increase in both TRM and rate of leukemic Philadelphia-positive clonogenic precursor cells and if relapse. The optimal timing of the transplant was found to these patients are still at risk of relapse. Recently, attenbe within 1 year from diagnosis where a small, but signifition has been drawn to the detection of the BCR-ABL cant survival benefit was observed, primarily due to a fusion message in apparently normal individuals. If proreduction in TRM. However, we could not confirm ven correct, this observation casts doubt on the signifiprevious findings that this survival benefit was particularly cance of positive PCR findings in long-term survivors of evident in patients who received CsA/MTX as GVHD marrow transplantation.
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prophylaxis.
13,21
GVHD and/or interstitial pneumonitis were responsible It has been previously reported that transplantation for for 54% of all deaths. The current study confirms that CML in accelerated or blastic phase carries an increased post-transplant immunosuppression with CsA/MTX is risk of leukemic relapse. 8 In the present study, which was more effective in reducing acute GVHD and TRM comconfined to CML in chronic phase, the probability of leupared to GVHD prophylaxis with CsA only. 1,2 Although kemic relapse was 19%. Disease-related variables, such as there was a trend towards better survival in the CsA/MTX WBC at diagnosis, were not associated with relapse, even group, these benefits did not translate into an improved if the analyses were adjusted for the method of GVHD LFS due to an increased relapse rate. New therapeutic prophylaxis and the incidence of acute or chronic GVHD.
approaches for the management of relapse have become However, chronic GVHD and male donor sex were strongly available in recent years. The initial experience with adopassociated with relapse. The probability of relapse for tive immunotherapy consisting of lymphocyte transfusion patients transplanted with marrow cells from a female from the original marrow donor suggest that approxidonor and who developed chronic GVHD was only 5%. In mately 70% of patients with relapsing disease can be salcontrast, the relapse rate in patients with a male sibling vaged. It seems likely therefore that in coming years more donor and no subsequent chronic GVHD reached 35%.
emphasis will be placed on reducing GVHD and acute Interestingly, the absence of chronic GVHD was a risk factoxicity at the time of the per primum transplant procedure tor for both early and late relapse, whilst male donor sex with the option of subsequent immune modulation with only increased the risk of late relapse. It was particularly donor cells in case of relapse. The present cohort did not striking that 14 out of 16 patients who relapsed more than have the benefit of recent advances in the management of 2 years after transplant were transplanted with marrow cells cytomegalovirus infection which is an important cause of from a male donor. The increased number of late relapses interstitial pneumonitis after transplant. 25 Early detection observed with the use of male donors could not only be and effective treatment of reactivation of cytomegalovirus accounted for by a reduction in chronic GVHD for both with ganciclovir has now become common practice and factors proved significant in multivariate analysis. These will serve to prevent CMV pneumonitis and further findings support the idea that immunological control of residual leukemia by donor cells is of paramount imporimprove outcome in future transplant cohorts.
